Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px
All >

Deals > Switzerland

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Switzerland or involving Swiss organisations.

Total search results: 797 | Ordered by Date (descending)
1 2 3 4 5 6 7 8  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering 2021-03-24
Monte Rosa Therapeutics–HBM: investment, 202103 financing round Series C totalling $95m incl existing + co-investor HBM Healthcare Investments 2021-03-12
Relief Therapeutics–OTHER: investment, 202103 private placement CHF10m with 41.5m shares at CHF0.2412/share with institutional US investor 2021-03-12
Silicon Therapeutics–Roivant: investment, 202102– acquisition $450m in shares + milestones by Roivant Sciences ANNOUNCED 2021-02-26
Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact 2021-02-11
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets 2021-02-04
Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund 2021-01-28
Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB 2021-01-26
TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund 2021-01-25
Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx 2021-01-21
AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones 2021-01-20
Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services 2021-01-20
LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG 2021-01-18
IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments 2021-01-13
Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake 2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP 2021-01-11
Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments 2021-01-11
SomaLogic–Novartis: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Novartis 2020-12-22
Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED 2020-12-17
NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer 2020-12-10
Novartis–RetinAI Medical: AI-based image analysis, 202012– collab expansion master agreement using RetinAI Discovery platform in ophthalmology 2020-12-08
RetinAI Medical–Charles Consultants: public relations, 202012 service existent by Sue Charles 2020-12-08
MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management 2020-12-01
MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science 2020-12-01
Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments 2020-11-30
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund 2020-11-23
SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation 2020-11-19
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties 2020-11-16
Start Codon–Novartis: investment, 202011 closing of Start Codon Fund I LP totalling £15m incl LP Novartis International AG 2020-11-16
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund 2020-11-10
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Memo Therapeutics–Bernina BioInvest: investment, 202011 financing round Series B totalling CHF14m incl new + co-investor Bernina BioInvest 2020-11-05
Memo Therapeutics–Halsin Partners: public relations, 202011 service existent by Halsin Partners 2020-11-05
Memo Therapeutics–Jaquet Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Jaquet Partners 2020-11-05
Memo Therapeutics–OTHER: investment, 202011 financing round Series B totalling CHF14m incl new private investors 2020-11-05
Memo Therapeutics–Redalpine: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Redalpine 2020-11-05
Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq 2020-11-05
Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB 2020-11-05
Memo Therapeutics–Verve Capital Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Investiere 2020-11-05
Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB 2020-11-05
Cara Therapeutics–Vifor Pharma: investment, 202010 equity investment $50m in connection with US license agreement for Korsuva 2020-10-20
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors 2020-10-15
Chord Therapeutics–Omega Funds: investment, 202010 financing Series A $16m from sole investor Omega Funds 2020-10-13
Chord Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund 2020-10-13
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
Sophia Genetics–ACE & Company: investment, 202010 financing round Series F totalling $110m incl new + co-investor ACE & Co 2020-10-01
Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo 2020-10-01
Sophia Genetics–aMoon: investment, 202010 financing round Series F totalling $110m incl co-lead investor aMoon 2020-10-01
Sophia Genetics–Credit Suisse: investment, 202010 financing round Series F totalling $110m incl co-investor Credit Suisse 2020-10-01
Sophia Genetics–Endeavour Vision: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Endeavour Vision 2020-10-01
Sophia Genetics–Eurazeo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Eurazeo Growth 2020-10-01
Sophia Genetics–Famille C Invest: investment, 202010 financing round Series F totalling $110m incl new + co-investor Famille C Invest 2020-10-01
Sophia Genetics–Generation Investment Management: investment, 202010 financing round Series F totalling $110m incl existing + co-investor GIM 2020-10-01
Sophia Genetics–Hitachi: investment, 202010 financing round Series F totalling $110m incl co-lead investor Hitachi Ventures 2020-10-01
Sophia Genetics–Pictet: investment, 202010 financing round Series F totalling $110m incl co-investor Pictet Group 2020-10-01
Sophia Genetics–SEVERAL: investment, 202010 financing round Series F $110m led by aMoon + Hitachi Ventures 2020-10-01
Sophia Genetics–Swisscom: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Swisscom Ventures 2020-10-01
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG 2020-09-28
Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group 2020-09-25
Immune Regulation–Metellus: investment, 202009– financing round Series B totalling £40.6m incl co-investor Metellus AG 2020-09-21
Inflazome–Roche: investment, 202009 acquisition of Inflazome by Roche for €380m upfront + milestones 2020-09-21
Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications 2020-09-16
Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact 2020-09-16
BioVersys–SEVERAL: investment, 202009 financing round Series B CHF19m 2020-09-01
Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 2020-09-01
Semalytix–btov Partners: investment, 202008 financing round Series A totalling €4.3m incl co-lead investor btov 2020-08-31
T-Knife–Versant Ventures: investment, 202008 financing round Series A totalling €66m incl new + co-lead investor Versant Ventures 2020-08-06
GentiBio–Novartis: investment, 202008 seed financing round totalling $20m inbcl co-lead investor Novartis Venture Fund 2020-08-05
Matterhorn Biosciences–Versant Ventures: investment, 202008– seed financing $30m commitment from Versant Ventures 2020-08-05
NBE Therapeutics–Optimum Strategic Communications: public relations, 202008 service existent by Optimum 2020-08-03
T3 Pharmaceuticals–Boehringer: investment, 202007 3rd financing round totalling CHF25m incl existing investor BIVF 2020-07-22
T3 Pharmaceuticals–OTHER: investment, 202007 3rd financing round totalling CHF25m incl existing private Swiss investors 2020-07-22
T3 Pharmaceuticals–Reference Capital: investment, 202007 3rd financing round totalling CHF25m incl existing investor Reference Capital SA 2020-07-22
T3 Pharmaceuticals–SEVERAL: investment, 202007 3rd financing round CHF25m from existing investors 2020-07-22
T3 Pharmaceuticals–Wille Finance: investment, 202007 3rd financing round totalling CHF25m incl existing investor Wille Finance AG 2020-07-22
Tubulis–BioMedPartners: investment, 202007 financing round Series A totalling €10.7m incl co-lead investor BioMedPartners 2020-07-21
Tubulis–Occident Group: investment, 202007 financing round Series A totalling €10.7m incl co-investor Occident Group 2020-07-21
TeleClinic–Zur Rose Group: investment, 202007– acquisition of TeleClinic GmbH for mid-double-digit million EUR price by Zur Rose Group 2020-07-16
Anergis–Virometix: allergy immunotherapy, 202007– collab research study at HZI using SVLPs supported by TRANSVAC2 grant in house dust mite allergy 2020-07-09
Resistell–EU (govt): grant, 202007 up to €2.5m grant + equity financing offer from EIC programme/fund 2020-07-03
Bright Peak Therapeutics–SEVERAL: investment, 202007 financing round Series A $35m 2020-07-01
CRISPR Therapeutics–SEVERAL: investment, 202006– public offering $450m+67.5m with 6.43m+964.3k common shares at $70/share 2020-06-29
Cutiss–Gisev Family Office: investment, 202006 financing round Series B totalling CHF20m incl lead investor Gisev Familiy Office 2020-06-29
Cutiss–SEVERAL: investment, 202006 financing round Series B CHF20m led by Gisev Familiy Office 2020-06-29
AdvanceCor–Occident Group: investment, 202006 financing round totalling €3.9m incl existing + co-investor Occident 2020-06-02
Monte Rosa Therapeutics–New Enterprise Associates: investment, 202005 discloses financing round Series A totalling $32.5m incl investor NEA 2020-05-26
Monte Rosa Therapeutics–SEVERAL: investment, 202005 emerges from stealth + discloses financing round Series A $32.5m from Versant + NEA 2020-05-26
Monte Rosa Therapeutics–Versant Ventures: investment, 202005 discloses financing round Series A totalling $32.5m incl founding investor Versant 2020-05-26
Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors 2020-05-19
Roche–Vividion Therapeutics: drug discovery, 202005– collab ww excl option + license agreem $135m upfront small molecules targeting E3 ligases 2020-05-19
CRISPR Therapeutics–Bank of America: investor conference, 202005 supply service CRISPR Tx presents at BofA Securities 2020 Health Care Conference 2020-05-14
Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform 2020-05-11
ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m 2020-05-01
Moderna–Lonza: biologicals contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products 2020-05-01
Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow 2020-04-28
Gustave Roussy–Biognosys: MS-based proteomics, 202004– collab using proteomic profiling in attempt to repurpose tocilizumab for Covid-19 2020-04-28
ADC Therapeutics–SEVERAL: investment, 202004–202005 IPO at NYSE $267.6m with 14.1m shares at $19/share 2020-04-24
1 2 3 4 5 6 7 8  next pagenext page



Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

» top